background
rapid
virolog
diagnosi
need
limit
length
isol
suspect
case
method
manag
first
patient
suspect
rapid
care
circuit
virolog
diagnosi
infecti
diseas
refer
hospit
marseil
franc
rapid
viral
detect
perform
sputum
nasopharyng
sampl
result
studi
period
detect
result
obtain
within
approxim
h
arriv
patient
sampl
laboratori
viral
infect
identifi
patient
common
pathogen
influenza
b
virus
rhinoviru
metapneumoviru
common
coronavirus
notabl
decemb
novel
coronaviru
name
identifi
caus
cluster
pneumonia
case
wuhan
citi
hubei
provinc
china
number
case
rapidli
rose
spread
global
within
day
focu
area
asia
europ
middl
east
epidemiolog
data
indic
humantohuman
transmiss
occur
march
confirm
case
report
franc
three
death
context
rapid
virolog
diagnosi
valuabl
reduc
durat
isol
suspect
case
reduc
fear
among
individu
potenti
ben
contact
also
allow
optim
manag
case
diagnos
aim
share
initi
experi
manag
patient
suspect
rapid
ambulatori
care
circuit
virolog
diagnosi
infecti
diseas
refer
hospit
marseil
franc
franc
definit
possibl
case
chang
studi
period
fig
mediterranean
infect
univers
hospit
institut
build
includ
hospit
bed
singl
room
like
convert
three
modul
neg
pressur
well
daycar
hospit
outpati
depart
consult
room
travel
clinic
part
outpati
depart
five
singl
room
isol
rest
depart
kept
neg
pressur
need
extend
entir
consult
ward
institut
also
includ
five
larg
laboratori
total
area
four
floor
diagnost
laboratori
research
laboratori
technolog
platform
infecti
diseas
specialist
avail
h
day
seven
day
week
telephon
counsel
emerg
unit
help
screen
case
collabor
region
public
health
servic
clinician
refer
suspect
patient
test
specif
outpati
unit
nurs
infecti
diseas
specialist
manag
patient
present
sever
symptom
arriv
other
hospitalis
highlevel
isol
unit
naso
oropharyng
swab
andor
sputum
obtain
patient
viral
rna
extract
nasoand
oropharyng
swab
fluid
andor
sputum
use
viru
mini
kit
courtaboeuf
franc
detect
rna
use
two
differ
rtpcr
system
hydrolysi
probe
lightcycl
multiplex
rna
viru
master
kit
roch
mannheim
germani
first
system
target
envelop
protein
e
encod
gene
previous
describ
use
synthet
rna
posit
control
suppli
virolog
institut
berlin
berlin
germani
second
system
design
inhous
target
spike
proteinencod
gene
forward
primer
revers
primer
probe
use
synthet
rna
posit
control
order
sera
belgium
case
realtim
rtpcr
carri
quantinova
sybr
green
rtpcr
kit
target
either
e
gene
primer
previous
describ
primer
target
rnadepend
rna
polymeras
rdrp
encod
gene
synthet
rna
posit
control
eurogentec
phage
rna
intern
control
ad
clinic
sampl
extract
ensur
rna
extract
pcr
amplif
accur
experi
perform
lightcycl
instrument
roch
diagnost
train
qualifi
technician
avail
januari
march
patient
admit
centr
suspect
three
patient
miss
travel
data
exclud
analysi
mark
increas
daili
number
patient
observ
februari
fig
patient
return
asia
includ
return
china
return
itali
patient
nt
travel
outsid
franc
consid
contact
case
mf
sex
ratio
mean
age
year
rang
year
includ
children
age
seven
age
three
patient
hospitalis
treat
outpati
tabl
twothird
patient
febril
respiratori
symptom
suggest
upper
respiratori
tract
infect
tabl
pcr
assay
neg
sampl
patient
measur
first
test
result
obtain
within
averag
min
rang
min
patient
sampl
arriv
laboratori
thereaft
result
continu
avail
approxim
h
viral
diagnosi
obtain
patient
tabl
frequent
virus
influenza
viru
patient
rhinoviru
influenza
b
viru
metapneumoviru
common
coronavirus
detect
patient
twelv
patient
viral
coinfect
tabl
pattern
viral
infect
slightli
differ
patient
return
itali
return
china
notabl
patient
return
itali
like
infect
influenza
b
viru
metapneumoviru
coronaviru
compar
return
asia
fig
contrast
patient
return
asia
like
infect
rhinovirusenteroviru
respiratori
syncyti
viru
infect
symptom
rang
unspecif
mild
respiratori
symptom
acut
respiratori
distress
symptom
similar
mani
season
virus
implement
outpati
rapid
diagnosi
mildli
affect
patient
oper
h
day
seven
day
week
involv
test
broad
spectrum
clinic
present
potenti
expos
person
itali
infecti
diseas
clinician
key
patient
triag
genom
sequenc
enabl
rapid
design
implement
dedic
pointofcar
realtim
rtpcr
diagnost
test
addit
respiratori
pathogen
test
mediterranean
infect
univers
hospit
institut
one
nine
french
metropolitan
hospit
centr
habilit
french
ministri
health
moh
manag
highli
contagi
patient
centr
design
moh
test
patient
suspect
earli
start
epidem
correspond
present
studi
among
nine
hospit
institut
one
organ
manag
larg
popul
outpati
dedic
isol
area
neg
pressur
laboratori
facil
site
number
french
centr
design
test
extend
hospit
final
march
french
moh
author
privat
medic
laboratori
perform
nasopharyng
sampl
test
franc
laboratori
manag
medic
doctor
pharmacist
clinic
featur
outpati
compat
prodrom
phase
previous
report
similar
earlier
studi
suspect
case
merscov
case
detect
wherea
common
viral
pathogen
detect
patient
result
patient
return
itali
corrobor
italian
studi
conduct
among
patient
januari
februari
regard
predomin
influenza
virus
among
posit
sampl
follow
rhinoviru
time
identif
influenza
viru
infect
allow
earli
treatment
antivir
therapi
respiratori
viru
acquisit
follow
travel
common
previou
studi
conduct
pilgrim
return
grand
mahal
seneg
hajj
kingdom
saudi
arabia
acquisit
rhinoviru
common
coronavirus
frequent
observ
addit
reveal
evid
metapneumoviru
account
also
signific
proport
posit
case
found
higher
proport
common
coronavirus
notabl
high
proport
common
coronavirus
reflect
circul
virus
commun
mainli
respons
mild
upper
respiratori
tract
infect
interestingli
found
sever
season
coronavirus
coinfect
influenza
b
virus
rhino
enterovirus
although
result
extrapol
inde
question
healthcar
set
diagnosi
avail
whether
diagnosi
influenza
rule
diagnosi
crossreact
common
coronavirus
common
virus
yet
describ
knowledg
role
viral
coinfect
diseas
sever
still
unknown
sar
cov
metapneumoviru
coinfect
document
correl
diseas
sever
earli
recognit
critic
isol
confirm
case
prevent
transmiss
unit
state
cdc
decid
mobilis
state
local
depart
order
obtain
collect
clinic
epidemiolog
data
describ
characterist
person
test
decreas
risk
global
dissemin
abl
make
prompt
medic
assess
rapid
biolog
diagnosi
suspect
patient
lead
much
easier
fast
manag
patient
short
turnaround
time
result
outpati
manag
make
possibl
reduc
time
need
introduc
specif
treatment
necessari
earli
ruleout
allow
public
health
contain
measur
adjust
reduc
time
spent
isol
nb
studi
period
seven
test
return
posit
patient
hospitalis
region
franc
whose
sampl
test
laboratori
march
new
patient
test
posit
hospit
none
declar
none
declar
